Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented promising results from multiple clinical studies at the 2025 ESMO Congress in Berlin, showcasing their innovative ADCs. Notably, their TROP2-directed ADC, sacituzumab tirumotecan (sac-TMT), demonstrated significant improvements in progression-free survival and overall survival in both non-small cell lung cancer and breast cancer trials when compared to traditional chemotherapy, indicating a potential shift in treatment paradigms for these cancers.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$548.60 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative drugs, particularly antibody-drug conjugates (ADCs) targeting various cancer types.
Average Trading Volume: 814,396
Technical Sentiment Signal: Buy
Current Market Cap: HK$106.9B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts